Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Norovirus Gastroenteritis Clear all
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

NCT05992935
View directory record Official record
Conditions
Norovirus Acute Gastroenteritis
Interventions
mRNA-1403, mRNA-1405, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
14
States / cities
Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 21, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults

NCT05972733
View directory record Official record
Conditions
Gastroenteritis
Interventions
HIL-214
Biological
Lead sponsor
HilleVax
Industry
Eligibility
18 Years to 49 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Rolling Hills Estates, California • Stockbridge, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jul 21, 2026, 5:02 PM EDT
Not listed No phase listed Observational

A Multi-Site Clinical Evaluation of the ARIES Norovirus Assay

NCT02092259
View directory record Official record
Conditions
Acute Gastroenteritis
Interventions
Not listed
Lead sponsor
Luminex Corporation
Industry
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Jul 21, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bivalent Norovirus Vaccine Study

NCT01168401
View directory record Official record
Conditions
Gastroenteritis
Interventions
NoV GI.1/GII.4 Bivalent VLP Vaccine, Saline
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
3
States / cities
Silver Springs, Maryland • St Louis, Missouri • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2018 · Synced Jul 21, 2026, 5:02 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Two Doses of HIL-214 in Children

NCT05281094
View directory record Official record
Conditions
Gastroenteritis
Interventions
HIL-214, Placebo
Biological
Lead sponsor
HilleVax
Industry
Eligibility
5 Months to 5 Months
Enrollment
3,084 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Jul 21, 2026, 5:02 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)

NCT02337842
View directory record Official record
Conditions
Gastroenteritis Norovirus
Interventions
Norovirus GII.4 Challenge Pool CIN-1, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Jul 21, 2026, 5:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Infectivity of Norovirus in Shellfish Treated With High Hydrostatic Pressure Processing-Human Challenge Study

NCT00674336
View directory record Official record
Conditions
Healthy
Interventions
High Hydrostatic Pressure Processing
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Jul 21, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

NNITS-Nitazoxanide for Norovirus in Transplant Patients Study

NCT03395405
View directory record Official record
Conditions
Gastroenteritis Norovirus
Interventions
Nitazoxanide, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
12
States / cities
Chicago, Illinois • Kansas City, Kansas • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jul 21, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies

NCT02473224
View directory record Official record
Conditions
Gastroenteritis Norovirus
Interventions
Norovirus GII.2 Challenge, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Jul 21, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

NCT03125473
View directory record Official record
Conditions
Norovirus Gastroenteritis
Interventions
VXA-G1.1-NN Oral Vaccine
Biological
Lead sponsor
Vaxart
Industry
Eligibility
19 Years to 49 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Jul 21, 2026, 5:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Infectivity of Norovirus in Groundwater-Human Challenge Study

NCT00313404
View directory record Official record
Conditions
Healthy
Interventions
Safety tested norovirus inoculum
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Jul 21, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

New Challenge Pool of Norwalk Virus Inoculum

NCT00138476
View directory record Official record
Conditions
Gastroenteritis Norovirus
Interventions
Placebo, Norwalk Virus
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jul 21, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase I Norovirus Challenge Model

NCT04174560
View directory record Official record
Conditions
Gastroenteritis Norovirus
Interventions
Norovirus GII.4 Challenge Pool
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Jul 21, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

NCT02868073
View directory record Official record
Conditions
Norovirus Gastroenteritis
Interventions
VXA-G1.1-NN (high dose) Oral Vaccine Tablet, VXA Placebo Tablets, VXA-G1.1-NN (low dose) Oral Vaccine Tablet
Biological · Other
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Jul 21, 2026, 5:02 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Norovirus Challenge Study

NCT05212168
View directory record Official record
Conditions
Norovirus Infections
Interventions
VXA-G1.1-NN, Placebo Tablets, Norovirus GI.1 Norwalk Virus Inoculum
Biological · Other
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jul 21, 2026, 5:02 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

NCT06592794
View directory record Official record
Conditions
Acute Gastroenteritis, Norovirus Acute Gastroenteritis
Interventions
mRNA-1403, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37,864 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
184
States / cities
Birmingham, Alabama • Cullman, Alabama • Daphne, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 21, 2026, 5:02 PM EDT